American Journal of Hematology · 2012 · 26 citations · 49 references
MedicineCell BiologyOncologyChemotherapyMolecular OncologyOncogenesCytotoxic ChemotherapyHematologic Malignancy TherapyOncogene ActivationOncogenic Signaling PathwaysPediatric LeukemiasProto-oncogene ActivationAcute Lymphoblastic Leukemia TreatmentB-cell Acute Lymphoblastic LeukemiaB-cell LeukemiaBcl2 InhibitionCell Cycle DynamicsCell Cycle InhibitionSurvival RatesTherapeutic Target Identification
Acute lymphoblastic leukemia (ALL) is the most common cancer in children. The current treatment protocol for ALL involves an intense chemotherapy regimen yielding cure rates of nearly 80%. However, new therapies need to be designed not only to increase the survival rate but also to combat the risk of severe therapy associated toxicities including secondary malignancies, growth problems, organ damage, and infertility. The c-Myb proto-oncogene is highly expressed in immature hematopoietic cells. In this study, we demonstrate that loss of c-Myb itself decreased the viability of these leukemic cells. Additionally, the inhibition of c-Myb caused a decrease in cell proliferation, significantly increased the number of cells in G(0) /G(1) phase of the cell cycle, increased the sensitivity of pre-B-ALL cells to cytotoxic agents in vitro, and significantly delayed disease onset in a mouse model of leukemia. Furthermore, we demonstrate that Bcl-2 is a target of c-Myb in pre-B-ALL cells. Our results identify c-Myb as a potential therapeutic target in pre-B-ALL and suggest that suppression of c-Myb levels or activity, in combination with currently used therapies and/or dose reduction, may lead to a decrease in toxicity and an increase in patient survival rates. Because c-Myb is aberrantly expressed in several other malignancies, targeting c-Myb will have broad clinical applications.
49
A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis
Michael L. Mucenski, Kersten McLain, Ann B. Kier et al. · Cell · 1991 · 1.1K citations
A putative second cell-derived oncogene of the avian leukaemia retrovirus E26
Dominique Leprince, Anne Gégonne, Jean‐Luc Coll et al. · Nature · 1983 · 459 citations